There is no deadline or definitive timetable set for completion of the strategic alternatives review process and there can be no assurance that this process will result in the Company pursuing a ...

FORT WORTH, Texas - PharmChem, Inc. (OTC: PCHM), known for its drug-detecting sweat patches and currently trading at $3.07 near its 52-week low, announced Monday that its Board of Directors is ...

SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (“Turnstone” or the “Company”) (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations, including the status of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

and halt further development of the program. Also, Turnstone’s management and its board of directors have initiated a process to explore and review strategic alternatives focused on maximizing ...

FORT WORTH, Texas, Feb. 3, 2025 /PRNewswire/ -- PharmChem, Inc.("PharmChem" or the "Company") (OTC: PCHM) the leading provider of sweat patches to detect drugs of abuse, today announced that the ...

Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations ...

Bausch Health will continue to own its 88% interest in Bausch + Lomb. Bausch Health, along with its financial and legal advisors, will continue its efforts to work on various liability management ...

As a result, Turnstone’s management and its Board of Directors have initiated a process to explore and review strategic alternatives focused on maximizing shareholder value. Turnstone has ...